The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
In the current AML treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?
Featured:
Uwe PlatzbeckerThe AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, In the current acute myeloid leukemia (AML) treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?
In the current AML treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?
Platzbecker begins by explaining that while both the symptoms of AML and treatment for AML can cause neutropenia, increasing patients’ susceptibility to bacterial or fungal infections, antibiotic prophylaxis is not normally recommended at this stage. He highlights the lack of randomized clinical trials investigating the use of general antibiotic prophylaxis in these patients, and differentiates this from neutropenic fever when antibiotic therapy is essential.
Platzbecker goes on to discuss antifungal prophylaxis, including a randomized clinical trial that has shown benefit of posaconazole compared with current standard of care, and how posaconazole prophylaxis is therefore recommended during intensive chemotherapy in patients with neutropenia. However, he highlights the cytochrome interactions necessitating dose reductions of venetoclax or ivosidenib when antifungal agents are given, and advises caution when using these combinations.
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?